Abstract
A battery of proinflammatory agents triggers the activation of NF-κB. This inducible transcription factor participates in the expression of an exceptionally large number of target genes, many of them contributing to the regulation of innate and adaptive immunity. Since some target genes also function as NF-κB activators, activation of this transcription factor allows the establishment of a signal amplification loop. Dysregulation of the NF-κB system and hyperactivated expression of inflammatory mediators are often found in association with some autoimmune diseases, which occur upon mounting of the adaptive immune response against self-antigens. In this review we summarize the relevance of aberrant NF-κB signaling for the development and perpetuation of some autoimmune diseases such as rheumatoid arthritis, diabetes mellitus type 1 and Crohns disease. The assets and drawbacks of systemic or cell-type specific NF-kB inhibitors and their potential use in therapy of autoimmune diseases are critically discussed.
Keywords: ikk, autoimmune disease, inflammation, crohns disease, rheumatoid arthritis
Current Pharmaceutical Design
Title: The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy
Volume: 10 Issue: 23
Author(s): Susanne Bacher and M. Lienhard Schmitz
Affiliation:
Keywords: ikk, autoimmune disease, inflammation, crohns disease, rheumatoid arthritis
Abstract: A battery of proinflammatory agents triggers the activation of NF-κB. This inducible transcription factor participates in the expression of an exceptionally large number of target genes, many of them contributing to the regulation of innate and adaptive immunity. Since some target genes also function as NF-κB activators, activation of this transcription factor allows the establishment of a signal amplification loop. Dysregulation of the NF-κB system and hyperactivated expression of inflammatory mediators are often found in association with some autoimmune diseases, which occur upon mounting of the adaptive immune response against self-antigens. In this review we summarize the relevance of aberrant NF-κB signaling for the development and perpetuation of some autoimmune diseases such as rheumatoid arthritis, diabetes mellitus type 1 and Crohns disease. The assets and drawbacks of systemic or cell-type specific NF-kB inhibitors and their potential use in therapy of autoimmune diseases are critically discussed.
Export Options
About this article
Cite this article as:
Bacher Susanne and Schmitz Lienhard M., The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy, Current Pharmaceutical Design 2004; 10 (23) . https://dx.doi.org/10.2174/1381612043383584
DOI https://dx.doi.org/10.2174/1381612043383584 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Strategies in the Treatment of Diabetic Nephropathy - a Translational Medicine Approach
Current Medicinal Chemistry Effects of Liver Diseases on Drug-metabolizing Enzymes: Implications for Drug Fate Alterations and Nano-therapeutic Openings
Current Medicinal Chemistry Editorial [Hot Topic: Pathogenesis and Treatment of Diabetic Complications,Retinopathy, Nephropathy and Cardiomyopathy (Executive Editor: J.L. Wilkinson-Berka)]
Current Pharmaceutical Design CXCR3-binding Chemokines: Novel Multifunctional Therapeutic Targets
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Insulin Decreases Therapeutic Efficacy in Colon Cancer Cell Line HT29 Via the Activation of the PI3K/Akt Pathway
Current Drug Discovery Technologies Inhibition of Protein Tyrosine Phosphatase 1B as a Potential Treatment of Diabetes and Obesity
Current Pharmaceutical Design Umbilical Cord Tissue Mesenchymal Stem Cells: Characterization and Clinical Applications
Current Stem Cell Research & Therapy Cardioprotective Properties of HDL: Structural and Functional Considerations
Current Medicinal Chemistry Sleep Duration as a Risk Factor for Cardiovascular Disease- a Review of the Recent Literature
Current Cardiology Reviews Changes in the Density of Corneal Endothelial Cells in Elderly Diabetic Patients After Combined Phacovitrectomy and Ex-PRESS Glaucoma Implants
Current Pharmaceutical Biotechnology Cloning, Expression and Characterization of Mouse (Mus musculus) Nicotinamide 5-Mononucleotide Adenylyltransferase-2
Medicinal Chemistry Other Potential Therapeutic Targets in Thyroid Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design Nutrition Status and Weight Management in Chinese Women
Current Women`s Health Reviews Evaluation of Antidiabetic Activity of Carnosol (Phenolic Diterpene in Rosemary) in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Disorders-Drug Targets Diabetes and Mortality in Acute Coronary Syndrome: Findings from the Gulf COAST Registry
Current Vascular Pharmacology Epidemiology of Hypertension and Diabetes Mellitus in Latin America
Current Hypertension Reviews Plasma Phospholipids are Associated with Mild Cognitive Impairment in Type 2 Diabetic Patients
Current Alzheimer Research Preface
Current Nutrition & Food Science Preventing Atherosclerosis with Angiotensin-Converting Enzyme Inhibitors: Emphasis on Diabetic Atherosclerosis
Current Drug Targets - Cardiovascular & Hematological Disorders